Tirzepatide vs Semaglutide: Key Differences & Side Effects


Tirzepatide vs semaglutide weight-loss results: ~20–21% average loss with tirzepatide vs ~15% with semaglutide (in separate trials). Compare differences, outcomes & side effects.
- How does tirzepatide vs semaglutide work? Tirzepatide works on two appetite signals (GLP-1 + GIP) while semaglutide works on one (GLP-1).
- What it can help with: feeling fuller sooner, eating smaller portions, and having fewer cravings.
- Most common side effects: nausea, reflux, constipation, diarrhea, vomiting (most often during dose increases).
- Gradual dosing: start low and increase over time to make it easier on your stomach.
- The right choice is personal: it depends on your health, goals, and coverage/access.

The Basics
If you’re comparing tirzepatide vs semaglutide, you’re not alone. Both are prescription medications typically taken as a weekly injection. Both may help curb appetite, which can make people feel less hungry and more satisfied after eating.
We’ll keep it easy: the differences, what they might feel like, and what to watch for so that you can decide with a licensed clinician what makes sense for you. Just a heads-up; this is general info, not medical advice. Everyone responds differently.
Who They’re For: Based on FDA Indications
- Weight management (adults): Wegovy® (semaglutide) and Zepbound® (tirzepatide) are indicated for adults with BMI ≥30, or BMI ≥27 with at least one weight-related condition.
- Type 2 diabetes: Ozempic® (semaglutide) and Mounjaro® (tirzepatide) are indicated (with diet and exercise) to improve blood sugar control in people with type 2 diabetes.
- Sleep apnea: Zepbound® is also indicated to treat moderate to severe obstructive sleep apnea in adults with obesity.
How Are They Different?
Both medications affect appetite and blood sugar signaling, but they’re not the same.
Semaglutide
Semaglutide is a GLP-1 receptor agonist.
Here’s what you might notice:
- Feeling fuller sooner
- Thinking about foods less often
- Having an easier time sticking to smaller portions
Tirzepatide
Tirzepatide acts on both GLP-1 and GIP receptors. Like semaglutide, tirzepatide can support appetite control–helping you feel full sooner and making cravings easier to manage.
On average, tirzepatide (as studied in the SURMOUNT trials and later marketed as Zepbound® for weight management and Mounjaro® for type 2 diabetes) tends to come out ahead in studies (about 20-21% vs about 15% in the STEP weight-management trials of semaglutide 2.4 mg [Wegovy®], a separate trial). But everyone’s experience is different, especially when it comes to side effects.
If you’re comparing semaglutide vs tirzepatide for weight management, this “one pathway vs two pathways” difference is usually the simplest place to start.
{{primary-cta}}
What Do These Medications Feel Like?
When someone starts treatment, they often say that it doesn’t feel dramatically different. But there’s less mental noise around food, and they have an easier time stopping when they’re satisfied.
People often describe:
- Less food noise (you still get hungry, but it doesn’t feel as urgent)
- More satisfaction from meals, so stopping earlier feels easier
- Less intense cravings, especially for sweets or snack foods
- Sometimes less interest in alcohol over time
Side Effects and Important Safety Notes
No matter which direction you’re leaning in the tirzepatide vs semaglutide conversation, the side effect list overlaps quite a bit.
- Common side effects
- Nausea
- Diarrhea
- Constipation
- Vomiting
- reflux/indigestion
- decreased appetite
These are often more noticeable during dose increases and may improve after your body adjusts.
Serious Risks And Warnings to Discuss With Your Doctor
These medications have important warnings and are not appropriate for everyone. A clinician may advise against use (or use extra caution) depending on your history, including:
- thyroid C-cell tumor warning (do not use if you or a family member has medullary thyroid cancer or MEN2)
- history of pancreatitis
- gallbladder disease
- kidney issues, especially if dehydration occurs from vomiting/diarrhea
- low blood sugar risk when combined with certain diabetes medications
- severe allergic reactions
Seek medical care promptly for severe or persistent abdominal pain, ongoing vomiting, dehydration symptoms, or anything that feels urgent.
{{primary-cta}}
How to Choose Between Semaglutide And Tirzepatide
Rather than asking which one is “best,” most clinicians think in terms of fit:
your medical history and current medications
- How sensitive your stomach tends to be
- Whether type 2 diabetes treatment is part of the picture
- Your goals and how you respond as the dose is adjusted
- What you can access (coverage, supply, out-of-pocket cost)
Helpful questions to ask:
- “What would you start with for someone like me—and why?”
- “If side effects show up, what’s the plan?”
- “How will we decide whether to adjust the dose or switch options?”
A Note on Compounded Medications (If They Come Up)
Compounded medications are not FDA-approved and do not undergo FDA review for safety, effectiveness, or manufacturing quality. A compounded medication may be prescribed only when a licensed prescriber determines a clinically significant difference for an identified patient. Formulations and potency may vary by pharmacy.
Ready For The Next Step?
If you’re deciding between tirzepatide vs semaglutide, the best next step is a clinical evaluation that looks at your health history, goals, and how you tend to tolerate side effects. With Eden, you can start by completing the intake, then a licensed provider reviews your information and helps you figure out what makes the most sense for your body and your goals. Not everyone qualifies, and eligibility depends on your health history.

Blog Components

The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.
Eden is not a medical provider. Eden connects individuals with independent licensed healthcare providers who independently evaluate each patient to determine whether a prescription treatment program is appropriate. All prescriptions are written at the sole discretion of the licensed provider. Medications are filled by state-licensed pharmacies. Please consult a licensed healthcare provider before making any medical decisions.
Frequently asked questions
Tirzepatide works on two appetite signals (GLP-1 + GIP), while semaglutide works on one (GLP-1). Both are used to support appetite control and feeling full, but they’re different medications.
On average, in large studies, people lost more weight with tirzepatide (about 20–21%) than with semaglutide (about 15%), but those numbers come from different trials. They’re helpful for setting expectations, not predicting your outcome. Your best option depends on your health history, goals, and side effects.
The most common side effects for both are nausea, reflux/indigestion, constipation, diarrhea, and vomiting (often during dose increases). Many people find symptoms improve as their body adjusts, but this varies, so it’s important to discuss side effects early on with your clinician.
No. Compounded meds are made by a pharmacy for a specific person. A prescriber should use them only if there’s a clinically significant difference needed for you specifically—meaning there’s a medical reason you need something meaningfully different than the standard, commercially made option. Because it’s prepared at the pharmacy, the exact mix and strength can vary.
Eli Lilly and Company. (2025). HIGHLIGHTS OF PRESCRIBING INFORMATION. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215866s034lbl.pdf
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., & Wharton, S. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4
HIGHLIGHTS OF PRESCRIBING INFORMATION. (2023). [Prescribing information]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/nejmoa2206038
Jastreboff, A. M., Roux, C. W. L., Stefanski, A., Aronne, L. J., Halpern, B., Wharton, S., Wilding, J. P. H., Perreault, L., Zhang, S., Battula, R., Bunck, M. C., Ahmad, N. N., & Jouravskaya, I. (2024). Tirzepatide for obesity Treatment and diabetes prevention. New England Journal of Medicine, 392(10), 958–971. https://doi.org/10.1056/nejmoa2410819
Mari, A., Stefanski, A., Van Raalte, D. H., Ma, X., LaBell, E. S., Fan, L., Lee, C. J., Thomas, M. K., Bunck, M. C., & Ferrannini, E. (2025). Tirzepatide treatment and associated changes in Β-Cell function and insulin sensitivity in people with obesity or overweight with prediabetes or normoglycemia: a post hoc analysis from the SURMOUNT-1 trial. Diabetes Care, 48(9), 1622–1627. https://doi.org/10.2337/dc25-0763
Min, T., & Bain, S. C. (2020). The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of Type 2 diabetes: the SURPASS Clinical Trials. Diabetes Therapy, 12(1), 143–157. https://doi.org/10.1007/s13300-020-00981-0
Novo Nordisk Inc. (2025). Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf
Novo Nordisk Inc. (2017b). OZEMPIC. https://www.novo-pi.com/ozempic.pdf
Pearcey, B. (2025, April 23). Weighing up the Risks: GI Side Effects of Semaglutide vs Tirzepatide. European Medical Journal. https://www.emjreviews.com/en-us/amj/gastroenterology/news/weighing-up-the-risks-gi-side-effects-of-semaglutide-vs-tirzepatide
Rodriguez, P. J., Cartwright, B. M. G., Gratzl, S., Brar, R., Baker, C., Gluckman, T. J., & Stucky, N. L. (2024). Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Internal Medicine, 184(9), 1056. https://doi.org/10.1001/jamainternmed.2024.2525
Wharton, S., Davies, M., Dicker, D., Lingvay, I., Mosenzon, O., Rubino, D. M., & Pedersen, S. D. (2021). Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgraduate Medicine, 134(1), 14–19. https://doi.org/10.1080/00325481.2021.2002616
Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/nejmoa2032183
Willard, F. S., Douros, J. D., Gabe, M. B., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., Van Der Velden, W. J., Stutsman, C., Cardona, G. R., Urva, S., Emmerson, P. J., Holst, J. J., D’Alessio, D. A., Coghlan, M. P., Rosenkilde, M. M., Campbell, J. E., & Sloop, K. W. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight, 5(17). https://doi.org/10.1172/jci.insight.140532
Thank you!
We'll be in touch.
Thank you!




















